Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
Scandinavian Journal of Gastroenterology|October 23, 2008
Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's diseaseCatherine Reenaers, Nathalie Franchimont, Cecile Oury, et al.Journal of Gastroenterology and Hepatology|August 30, 2007
Clinical and genetic factors associated with sacroiliitis in Crohn's diseaseHarald Peeters, Bert Vander Cruyssen, Herman Mielants, et al.Pharmacogenetics and Genomics|April 13, 2006
Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort studyVinciane Dideberg, Edouard Louis, Frédéric Farnir, et al.Digestive Diseases and Sciences|January 18, 2006
Hepatitis C virus genotype 5 in southern belgium: epidemiological characteristics and response to therapyJean Delwaide, Christiane Gerard, Catherine Reenaers, et al.Pharmacogenetics and Genomics|September 27, 2006
The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's diseaseVinciane Dideberg, Emilie Théâtre, Frédéric Farnir, et al.Pharmacogenetics and Genomics|December 14, 2005
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's diseaseStéphanie Willot, Severine Vermeire, Marc Ohresser, et al.Biochemical Pharmacology|January 30, 2007
Biomarker discovery for inflammatory bowel disease, using proteomic serum profilingMarie-Alice Meuwis, Marianne Fillet, Pierre Geurts, et al.Clinical Biochemistry|May 21, 2008
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot studyMarie-Alice Meuwis, Marianne Fillet, Laurence Lutteri, et al.Human Molecular Genetics|September 21, 2007
An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseasesVinciane Dideberg, Gudlaug Kristjansdottir, Lili Milani, et al.The American Journal of Gastroenterology|October 3, 2002
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's diseaseSeverine Vermeire, Edouard Louis, An Carbonez, et al.Pageof 3